Risperidone versus haloperidol: II. Cost-effectiveness

Clinical Therapeutics

Volumn 20, Issue 1, 1998, Pages 196-213

  Davies, Alison ^a   Langley, Paul C ^b   Keks, Nicholas A ^c   Catts, Stanley V ^d   Lambert, Tim ^e   Schweitzer, Isaac ^f  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b UNIVERSITY OF COLORADO   (United States)

^c ALFRED HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e Vic Transcultural Psychiatry Unit   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cost effectiveness; Haloperidol; Health economics; Risperidone; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; RISPERIDONE;

AUSTRALIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL COST; HUMAN; META ANALYSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031905744     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80046-5     Document Type: Note

References (29)

1. Eaton W. Epidemiology of schizophrenia. Epidemiol Rev. 1985;7:105-126.
2. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Arch Gen Psychiatry. 1985;42:537-543.
3. Andrews G. The cost of schizophrenia revisited. Schizophr Bull. 1991;17:389-394.
4. Rice DP, Miller LS. The economic burden of schizophrenia. Paper presented at the 6th Biennial Research Conference on the Economics of Mental Health: September 21-22, 1992; Bethesda, Md.
5. Baldessarini R. Drugs and the treatment of psychiatric disorders. In: Gilman A, Goodman LS, Goodman A, eds. Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan; 1975:391-447.
6. Meltzer HY. Clozapine and other atypical neuroleptics: Efficacy, side effects, optimal utilization. J Clin Psychiatry. 1994; 12:38-45. Monograph.
7. Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: I. Metaanalysis of efficacy and safety. Clin Ther. 1997;19:58-71.
8. Hoyberg OJ. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88: 395-402.
9. Huttunen MO, Pieponneu T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: A double blind parallel-group trial. Acta Psychiatr Scand. 1995;91: 271-277.
10. Drummond M, Rutten F, Brenna A, et al. Economic evaluation of pharmaceuticals. A European perspective. PharmacoEconomics. 1993;4:173-186.
11. Commonwealth of Australia. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Commonwealth Department of Health Housing and Community Services: 1993.
12. Click H, Kinosian B, Schulman K. Decision analytic modeling: Some uses in the evaluation of new pharmaceuticals. Drug Inf J. 1994;28:691-707.
13. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clin Ther. 1993;15:917-926.
14. Lindström E, von Knorring L, Eberhard G. Studies of selected outcome-related clinical parameters following short-term and long-term treatment with risperidone. Neuropsychopharmacology. 1994:10 (Suppl. Pt 2):150S. Abstract.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
16. Psychotropic Drug Guidelines Sub-Committee, Victorian Drug Usage Advisory Committee. Psychotropic Drug Guidelines. 3rd ed. Melbourne, Australia: Victorian Medical Postgraduate Foundation; 1995.
17. Commonwealth of Australia. Schedule of Pharmaceutical Benefits. Canberra, Australia: Commonwealth Department of Health Housing and Community Services; 1993.
18. Australian Approved Product Information for Risperdal. Janssen-Cilag Pty. Ltd., Lane Cove, Australia, 1994.
19. Treatment of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 12B):4-29.
20. Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society; 1996:714-715.
21. Badewitz-Dodd LH, ed. 1996 MIMS Annual. 20th ed. St. Leonards, Australia: MIMS Australia.
22. Commonwealth of Australia. Manual of Resource Items and Their Associated Costs for Use in Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Commonwealth Department of Health Housing and Community Services; 1993.
23. Commonwealth of Australia. Medicare Benefits Schedule Book. Canberra, Australia: Commonwealth Department of Health Housing and Community Services; 1993.
24. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment resistant schizophrenia in the United Kingdom. Br J Psychiatry. 1993; 162:38-42.
25. Drummond MF, Bloom BS, Canin G, et al. Issues in the cross national assessment of health technology. Int J Technol Assess Health Care. 1992;8:671-682.
26. Kane JM, Borenstein M. Compliance in the long term treatment of schizophrenia. Psychopharmacol Bull. 1985;21:23-27.
27. Moeller HJ. Open study on the long-term treatment of chronic schizophrenia patients with risperidone. Analysis of efficacy and safety data. Clinical Research Report on R64766 RIS-INT-4. Janssen Pharmaceutical, Beerse, Belgium, 1993.
28. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin Drug Invest. 1996;11:289-299.
29. Maynard A, Bloor K. Economic evaluation of mental health services. Curr Opin Psychiatry. 1995;8:122-125.